Synthesis, molecular docking, and biological evaluation of 3-oxo-2-tolylhydrazinylidene-4,4,4-trifluorobutanoates bearing higher and natural alcohol moieties as new selective carboxylesterase inhibitors. 2019

Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia.

To search for effective and selective inhibitors of carboxylesterase (CES), a series of 3-oxo-2-tolylhydrazinylidene-4,4,4-trifluorobutanoates bearing higher or natural alcohol moieties was synthesized via pre-transesterification of ethyl trifluoroacetylacetate with alcohols to isolate transesterificated oxoesters as lithium salts, which were then subjected to azo coupling with tolyldiazonium chloride. Inhibitory activity against porcine liver CES, along with two structurally related serine hydrolases, acetylcholinesterase and butyrylcholinesterase, were investigated using enzyme kinetics and molecular docking. Kinetics studies demonstrated that the tested keto-esters are reversible and selective mixed-type CES inhibitors. Analysis of X-ray crystallographic data together with our IR and NMR spectra and QM calculations indicated that the Z-isomers were the most stable. The kinetic data were well explained by the molecular docking results of the Z-isomers, which showed specific binding of the compounds in the CES catalytic active site with carbonyl oxygen atoms in the oxyanion hole and non-specific binding outside it. Some compounds were studied as inhibitors of the main human isozymes involved in biotransformation of ester-containing drugs, hCES1 and hCES2. Esters of geraniol (3d) and adamantol (3e) proved to be highly active and selective inhibitors of hCES2, inhibiting the enzyme in the nanomolar range, whereas esters of borneol (3f) and isoborneol (3g) were more active and selective against hCES1. Computational ADMET studies revealed that all test compounds had excellent intestinal absorption, medium blood-brain barrier permeability, and low hERG liability risks. Moreover, all test compounds possessed radical-scavenging properties and low acute toxicity. Overall, the results indicate that members of this novel series of esters have the potential to be good candidates as hCES1 or hCES2 inhibitors for biomedicinal applications.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006845 Hydrocarbons, Fluorinated Inert liquid or gaseous halocarbon compounds in which FLUORINE replaces some or all HYDROGEN atoms. Fluorinated Hydrocarbons
D000438 Alcohols Alkyl compounds containing a hydroxyl group. They are classified according to relation of the carbon atom: primary alcohols, R-CH2OH; secondary alcohols, R2-CHOH; tertiary alcohols, R3-COH. (From Grant & Hackh's Chemical Dictionary, 5th ed)
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
January 2015, Doklady. Biochemistry and biophysics,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
March 2016, Bioorganic & medicinal chemistry,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
December 2016, Bioorganic chemistry,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
August 2017, Bioorganic & medicinal chemistry,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
October 2017, Molecules (Basel, Switzerland),
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
January 2020, Current Alzheimer research,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
November 2020, Bioorganic chemistry,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
September 2015, Bioorganic & medicinal chemistry,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Galina F Makhaeva, and Natalia A Elkina, and Evgeny V Shchegolkov, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Eugene V Radchenko, and Vladimir A Palyulin, and Yanina V Burgart, and Victor I Saloutin, and Sergey O Bachurin, and Rudy J Richardson
May 2014, European journal of medicinal chemistry,
Copied contents to your clipboard!